Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects (Q34451719)

2 August 2017

1 reference

title

Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects (English)

1 reference

polycystic ovary syndrome

2 August 2017

1 reference

1 reference

1 reference

Nardo LG

1

1 reference

PubMed ID

11727360

2 August 2017

Rai R

series ordinal

2

1 reference

2 August 2017

1 October 2001

1 reference

Gynecological Endocrinology

2 August 2017

1 reference

2 August 2017

15

1 reference

2 August 2017

5

1 reference

2 August 2017

373-380

1 reference

On the paradox of insulin-induced hyperandrogenism in insulin-resistant states

2 August 2017

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

The genetic basis of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Disturbances in insulin secretion and sensitivity in women with the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Polycystic ovaries and recurrent miscarriage--a reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

The importance of diagnosing the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Managing hirsutism in gynaecological practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

Effects of insulin-like growth factors I and II and insulin on the immortalized hypothalamic GTI-7 cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2FGYE.15.5.373.380

21 January 2018

Identifiers

DOI

10.1080/GYE.15.5.373.380

1 reference

2 August 2017

1 reference

PubMed ID

11727360